# Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

> **NCT00195091** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tetrathiomolybdate

## Key facts

- **NCT ID:** NCT00195091
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** 2023-03-02
- **Final completion:** 2023-03-02
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** PI left MSKCC
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195091, "Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00195091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*